VistaGen Therapeutics share price logo

VistaGen Therapeutics

NASDAQ: VTGN

$0.24

+0.00

(+0.87%)

as on

VistaGen Therapeutics Stock Performance

as on August 20, 2026 at 2:15 pm IST

  • Day's Low

    Day's High

    $0.24
    $0.25
    downward going graph

    1.68%

    Downside

    2.42%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $0.20
    $5.14
    downward going graph

    18.89%

    Downside

    2005.69%

    Upside

    downward going graph

VistaGen Therapeutics share price movements today

Previous Close
$0.24
Open
$0.24
Volume
800.8K
Market Cap
$11.9M
Day's Low - High
$0.24 - $0.25
52 Week Low - High
$0.20 - $5.14

VistaGen Therapeutics Historical Returns

1 Month Return
+ 16.75 %
3 Month Return
-57.18 %
1 Year Return
-91.92 %
3 Year Return
-95.17 %
5 Year Return
-99.67 %

VistaGen Therapeutics Stock Fundamentals & Key Indicators

Check VistaGen Therapeutics market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$11.9M

EPS (TTM)

-1.87

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

-0.14

Industry PE ratio

-1.5966015625

PEG Ratio

0.0122975588448208

EBITDA

-69.4M

Revenue (TTM)

1.3M

Profit Margin

71.81%

Return On Equity TTM

-133.02%

VistaGen Therapeutics Stock Valuation

Track how VistaGen Therapeutics P/E has moved over time to understand its valuation trends.

VistaGen Therapeutics in the last 5 years

  • Overview

  • Trends

Lowest (-5.14x)

March 31, 2022

Industry (-1.60x)

March 31, 2026

Today (-0.31x)

March 31, 2026

Highest (-0.31x)

March 31, 2026

LowHigh

Today’s Price to Earnings Ratio: -0.31x

VistaGen Therapeutics vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of VistaGen Therapeutics with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
VistaGen Therapeutics image
VistaGen Therapeutics
BUY$11.9M-99.67%-0.1471.81%NA
Revolution Medicines image
Revolution Medicines
BUY$43.7B669.3%NA0.00%NA
Vertex Pharmaceuticals image
Vertex Pharmaceuticals
BUY$128.2B154.86%29.8286.04%NA
Regeneron image
Regeneron
BUY$82.7B24.1%19.2484.86%0.44999999999999996%

Stock Returns calculator for VistaGen Therapeutics Stock including INR - Dollar returns

The VistaGen Therapeutics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

VistaGen Therapeutics investment value today

Current value as on today

₹8,110

Returns

-₹91,890

(-91.89%)

Returns from VistaGen Therapeutics Stock

-₹92,625 (-92.63%)

Dollar Impact

₹735 (+0.74%)

Analyst Recommendation on VistaGen Therapeutics Stock

Based on 2 analysts

BUY

0.00%

Buy

100.00%

Hold

0.00%

Sell

Based on 2 analysts, 100% of analysts recommend a 'BUY' rating for VistaGen Therapeutics. Average target price of $1

VistaGen Therapeutics Share Price Target

Get share price movements and forecasts by analysts on VistaGen Therapeutics.

What analysts predicted

75.59%UPSIDE

Target Price

$1

Current Price

$0.2441

Analyzed by

2 Analysts

Target

$1.00

VistaGen Therapeutics target price $1, a slight upside of 75.59% compared to current price of $0.2441. According to 2 analysts rating.

Indian Investors' Interest in VistaGen Therapeutics Stock

Search interest for VistaGen Therapeutics Stock has decreased by -31% in the last 30 days, reflecting a downward trend in search activity.

Time period: to

Change:-31% versus previous 30 day period

VistaGen Therapeutics Quarterly Profit & Loss

All numbers in Millions USD

Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Total Revenue
0
0
0
0
0
0
0
0
0
0
Gross Profit
0
0
0
0
0
0
0
0
0
0
Operating Income
-7
-11
-12
-14
-15
-14
-15
-20
-19
-16
EBITDA
-7
-11
-10
-12
-13
-13
-14
-19
-18
-16
Interest Expense
-
-
-
-
-
-
-
-
-
-
Depreciation
0
0
0
0
0
0
0
0
0
0
Income Before Tax
-6
-9
-10
-12
-14
-13
-15
-19
-18
-16
Income Tax Expense
-
0
-
0
-
-
-
-
-
0
Net Income
-6
-9
-10
-12
-14
-13
-15
-19
-18
-16
Net Profit Margin
100.00%
100.00%
100.00%
100.00%
100.00%
100.00%
30.74%
100.00%
37.62%
100.00%

VistaGen Therapeutics Annual Profit & Loss

All numbers in Millions USD

Mar 2017
Mar 2018
Mar 2019
Mar 2020
Mar 2021
Mar 2022
Mar 2023
Mar 2024
Mar 2025
Mar 2026
Total Revenue
1
-
-
-
1
1
0
1
0
1
Gross Profit
1
-
-
0
1
1
0
1
0
1
Operating Income
-10
-14
-24
-19
-17
-47
-59
-33
-55
-72
EBITDA
-9
-14
-24
-20
-17
-47
-58
-28
-50
-71
Interest Expense
0
0
0
0
0
-
0
-
-
-
Depreciation
0
0
0
0
0
0
0
0
0
0
Income Before Tax
-10
-14
-24
-20
-17
-47
-59
-29
-51
-69
Income Tax Expense
0
0
0
0
0
0
0
0
0
0
Net Income
-10
-14
-24
-20
-17
-47
-59
-29
-51
-69
Net Profit Margin
100.00%
0.00%
0.00%
0.00%
100.00%
100.00%
100.00%
100.00%
100.00%
100.00%

VistaGen Therapeutics Quarterly Cash Flow

All numbers in Millions USD

Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Net Income
-6
-9
-10
-12
-14
-13
-15
-19
-18
-16
Operating Cash Flow
-4
-7
-10
-10
-10
-10
-18
-13
-17
-16
Investing Cash Flow
0
0
-5
-7
0
0
0
0
0
0
Financing Cash Flow
93
0
0
-
1
1
1
27
2
0
Change in Cash
88
-7
-16
-18
-9
-7
-18
13
-15
-16

VistaGen Therapeutics Annual Cash Flow

All numbers in Millions USD

Mar 2017
Mar 2018
Mar 2019
Mar 2020
Mar 2021
Mar 2022
Mar 2023
Mar 2024
Mar 2025
Mar 2026
Net Income
-10
-14
-24
-20
-17
-47
-59
-29
-51
-69
Operating Cash Flow
-7
-9
-14
-15
-12
-45
-49
-25
-42
-66
Investing Cash Flow
0
0
0
-
0
0
0
0
-13
0
Financing Cash Flow
9
16
17
4
114
10
-1
128
3
30
Change in Cash
2
7
2
-11
101
-34
-51
102
-52
-36

Mutual Funds that own VistaGen Therapeutics Stock

Check out the Mutual Funds with significant holdings in VistaGen Therapeutics.

Funds
Holdings
Shares Held
VANGUARD INDEX FUNDS
3.54734%
1574200
Fidelity Concord Street Trust
0.765787%
339833
Victory Portfolios III
0.008675%
3850
John Hancock Variable Insurance Trust
0.004867%
2160

Global Institutional Holdings in VistaGen Therapeutics

Funds
Holdings
Vanguard
3.55%
AdvisorShares
1.1%

VistaGen Therapeutics News & Key Events

  • img

    Today's Timeline - 19 May

    Tue, 04:38 PM

    -

    Vistagen shares early findings from Phase 3 PALISADE-3 study on fasedienol for social anxiety disorder, showing strong tolerability and gradual benefits.

    Tue, 06:00 PM

    -

    Vistagen appoints Angel S. Angelov as Chief Medical Officer, granting him an option to purchase 150,000 shares at $0.5955 each.

Insights on VistaGen Therapeutics

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Profit Spike

    img

    Netprofit is up for the last 4 quarters, -19.41M → -13.03M (in $), with an average increase of 14.6% per quarter

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Revenue is up for the last 6 quarters, -15.0K → 1.47M (in $), with an average increase of 46.0% per quarter

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Revolution Medicines, Inc. Common Stock has given 624.7% return, outperforming this stock by 720.3%

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Revolution Medicines, Inc. Common Stock has given 493.6% return, outperforming this stock by 585.7%

  • imgNEGATIVE IMPACT

    Price Dip

    img

    In the last 7 days, VTGN stock has moved down by -8.3%

About VistaGen Therapeutics

Vistagen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for neuropsychiatric and neurological disorders. The company's product pipeline includes Fasedienol, an investigational pherine nasal spray that is in Phase III clinical trial for the treatment of anxiety in adults with social anxiety disorder; and Itruvone, an odorless synthetic investigational neuroactive pherine nasal spray, which is in Phase IIa clinical trial to treat major depressive disorder. It also develops refisolone, an odorless and tasteless synthetic investigational pherine nasal spray that is in Phase IIa clinical trial for the treatment of vasomotor symptoms, including hot flashes due to menopause, premenstrual dysphoric disorder, and other women's health disorders; PH15, an investigational pherine nasal spray, which is in Phase IIa clinical trial for the treatment to improve cognitive impairment caused by mental fatigue disorders; PH284, an odorless and tasteless synthetic investigational pherine nasal spray that is in Phase IIa clinical trial to treat loss of appetite associated with chronic disorders, such as cancer cachexia; and AV-101, an oral prodrug that targets N-methyl-D-aspartate receptor in the brain for treating depression and neurological disorders. It has a license and collaboration agreement with AffaMed Therapeutics, Inc. to develop, manufacture, and commercialize fasedienol for multiple anxiety-related disorders. Vistagen Therapeutics, Inc. was founded in 1998 and is headquartered in South San Francisco, California.
OrganisationVistaGen Therapeutics
Headquarters343 Allerton Avenue, South San Francisco, CA, United States, 94080
IndustryBiotechnology
CEOMr. Shawn K. Singh J.D.
E-voting on sharesClick here to vote

Key Management of VistaGen Therapeutics

Name

Title

Dr. Allen Easley Cato III, M.D., Ph.D.

Senior Vice President of Integrated Drug Development

Dr. Mark J. Ginski Ph.D.

Senior VP and Head of Chemistry, Manufacturing & Controls

Dr. Louis Monti M.D., Ph.D.

Senior Vice President of Translational Neuroscience

Mr. Nick B. Tressler M.B.A.

CFO & Treasurer

Ms. Elissa Cote

Chief Corporate Development & Strategy Officer

Mr. Mark Adrian McPartland

Senior Vice President of Investor Relations

Ms. Trisha Fitzmaurice

Senior Vice President of Human Resources

Mr. Shawn K. Singh J.D.

President, CEO & Director

Mr. Joshua S. Prince M.B.A.

Chief Operating Officer

Mr. Reid G. Adler Esq., J.D.

Chief Legal Officer

FAQs

What is VistaGen Therapeutics share price today?

VistaGen Therapeutics share price today is $0.24 as on at the close of the market. VistaGen Therapeutics share today touched a day high of $0.25 and a low of $0.24.

What is the 52 week high and 52 week low for VistaGen Therapeutics share?

VistaGen Therapeutics share touched a 52 week high of $5.14 on and a 52 week low of $0.20 on . VistaGen Therapeutics stock price today i.e. is closed at $0.24,which is 95.25% down from its 52 week high and 23.28% up from its 52 week low.

What is VistaGen Therapeutics's market capitalisation today?

VistaGen Therapeutics market capitalisation is $0.00T as on .

How to invest in VistaGen Therapeutics Stock (VTGN) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for VistaGen Therapeutics on INDmoney app. Click on Buy button. You can invest as low as $1.5 in VistaGen Therapeutics Shares that will get you 6.1450 shares as per VistaGen Therapeutics share price of $0.24 per share as on August 20, 2026 at 8:45 am IST.

What is the minimum amount required to buy VistaGen Therapeutics Stock (VTGN) from India?

Indian investors can start investing in VistaGen Therapeutics (VTGN) shares with as little as ₹95.695 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹956.95 in VistaGen Therapeutics stock (as per the Rupee-Dollar exchange rate as on ). Based on VistaGen Therapeutics share’s latest price of $0.24 as on August 20, 2026 at 8:45 am IST, you will get 40.9668 shares of VistaGen Therapeutics. Learn more about fractional shares .

What are the returns that VistaGen Therapeutics has given to Indian investors in the last 5 years?

VistaGen Therapeutics stock has given -99.67% share price returns and 28.59% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?